Since our results have shown that αSyn co-pathology accelerates the Aβ-associated aggregation of tau pathology in AD, the presence of αSyn co-pathology may be a limiting factor for anti-Aβ drugs to prevent downstream tau aggregation. The gene discussed is MAPT; the disease is Alzheimer disease.